[{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SK10","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling","graph3":"Zhiyi Biotech","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhiyi Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Zhiyi Biot.."},{"orgOrder":0,"company":"Zhiyi Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhiyi Biotech Completes Phase I Trial of SK10 for Chemotherapy-Induced Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"SK10","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Zhiyi Biotech","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Zhiyi Biotech \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Zhiyi Biot.."}]

Find Clinical Drug Pipeline Developments & Deals by Zhiyi Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : SK10, the first Bacteroides fragilis-based LBP, has potential to mitigate 5-FU-induced injury via mitochondrial apoptotic BCL2/BAX pathway, is being explored for chemotherapy-induced diarrhea.

                          Product Name : SK10

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 05, 2024

                          Lead Product(s) : SK10

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Pre-clinical studies have indicated that SK10 can reduce the toxicity of chemotherapeutic drugs towards intestinal epithelial cells, regulate the expression of apoptosis-related proteins, reduce inflammat...

                          Product Name : SK10

                          Product Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 18, 2022

                          Lead Product(s) : SK10

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : IND Enabling

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank